Tesamorelin Side Effects
Tesamorelin is the only FDA-approved GHRH-class peptide, with a favorable safety profile relative to direct growth hormone. Its main monitoring concern is the GH/IGF-1 axis and glucose.
When they appear & how long they last
Effects tend to relate to the rise in IGF-1 and any fluid-retention response in the first weeks. IGF-1 should be checked around 6 weeks to confirm the response sits in range rather than overshooting.
Commonly reported Tesamorelin side effects
The most-reported effect - redness, itching, or irritation at the daily SC site.
Classic GH-axis effects from rising IGF-1; often mild.
From mild fluid retention pressing on nerves.
GH-axis stimulation can nudge fasting glucose upward.
When to contact your provider
- Persistent or worsening swelling (fluid retention)
- Fasting glucose trending out of range (insulin-resistance signal)
- Numbness/tingling that does not resolve
- Any allergic-reaction signs
Biomarkers worth tracking on Tesamorelin
These catch issues early - before you feel them. Pull a baseline before you start, then re-check on the cadence noted below.
The primary monitoring marker - check at ~6 weeks to confirm an in-range response.
GH-axis stimulation can raise glucose; watch the trend.
Longer-window glycemic read alongside fasting glucose.
How to actually track Tesamorelin side effects
Tesamorelin monitoring is IGF-1-centric: pull a baseline, then re-check around 6 weeks to see where your response landed. Track fasting glucose in parallel because the GH axis can mildly raise it. Note any joint aches or swelling against your dose - those fluid-retention effects usually tell you the dose is at the upper edge of your tolerance.
Track Tesamorelin with MyProtocolStack →